FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1996426161> ?p ?o ?g. }

• W1996426161 endingPage "1529" @default.
• W1996426161 startingPage "1524" @default.
• W1996426161 abstract "No AccessJournal of UrologyInvestigative Urology1 Oct 2011The Combination of Serenoa Repens, Selenium and Lycopene is More Effective Than Serenoa Repens Alone to Prevent Hormone Dependent Prostatic Growth Domenica Altavilla, Alessandra Bitto, Francesca Polito, Natasha Irrera, Herbert Marini, Salvatore Arena, Vincenzo Favilla, Francesco Squadrito, Giuseppe Morgia, and Letteria Minutoli Domenica AltavillaDomenica Altavilla Section of Pharmacology, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy More articles by this author , Alessandra BittoAlessandra Bitto Section of Pharmacology, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy More articles by this author , Francesca PolitoFrancesca Polito Section of Physiology and Human Nutrition, Department of Biochemical, Physiological and Nutritional Sciences, University of Messina, Messina, Italy More articles by this author , Natasha IrreraNatasha Irrera Section of Pharmacology, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy More articles by this author , Herbert MariniHerbert Marini Section of Physiology and Human Nutrition, Department of Biochemical, Physiological and Nutritional Sciences, University of Messina, Messina, Italy More articles by this author , Salvatore ArenaSalvatore Arena Department of Urology, University of Messina, Messina, Italy More articles by this author , Vincenzo FavillaVincenzo Favilla Department of Urology, Polyclinic Hospital, University of Catania, Catania, Italy More articles by this author , Francesco SquadritoFrancesco Squadrito Section of Pharmacology, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy More articles by this author , Giuseppe MorgiaGiuseppe Morgia Department of Urology, Polyclinic Hospital, University of Catania, Catania, Italy More articles by this author , and Letteria MinutoliLetteria Minutoli Section of Pharmacology, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.05.049AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Serenoa repens is frequently combined with other natural compounds, such as the carotenoid lycopene and the essential trace element Se, to increase its therapeutic activity in benign prostatic hyperplasia. We noted that the lycopene-Se-Serenoa repens combination has greater, enhanced anti-inflammatory activity, which might be of particular interest for benign prostatic hyperplasia treatment. Testosterone administration in rats is a suitable tool for investigating hormone dependent benign prostatic hyperplasia. We performed a comparison experiment between Serenoa repens and the lycopene-Se-Serenoa repens combination on prostate growth induced in rats by testosterone administration. Materials and Methods: Rats were treated daily with testosterone propionate (3 mg/kg subcutaneously) or its vehicle for 14 days. Testosterone administered animals were randomized to receive vehicle, Serenoa repens (25 mg/kg subcutaneously) or the combination of lycopene (3 mg/kg subcutaneously), Se (3 mg/kg subcutaneously) and Serenoa repens for 14 days. The rats were sacrificed and the prostate was removed for analysis. Results: Lycopene-Se-Serenoa repens was more effective than Serenoa repens alone for decreasing prostate weight and hyperplasia, augmenting pro-apoptotic Bax and caspase-9, and blunting anti-apoptotic Bcl-2 mRNA. Lycopene-Se-Serenoa repens also markedly decreased epidermal growth factor and vascular endothelial growth factor expression. Conclusions: The data indicate that the lycopene-Se-Serenoa repens combination is superior to Serenoa repens alone for decreasing hormone dependent prostatic growth. References 1 : Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am2011; 95: 87. Google Scholar 2 : The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol2008; 179: 1235. Link, Google Scholar 3 : Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res2006; 66: 5012. Google Scholar 4 : Clinical management of lower urinary tract symptoms with combined medical therapy. BJU Int2008; 102: 13. Google Scholar 5 : Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment. Urology2003; 62: 24. Google Scholar 6 : Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?. Eur Urol2007; 51: 1202. Google Scholar 7 : Growth factors in benign prostatic hyperplasia: basic science implications. Curr Urol Rep2008; 9: 272. Google Scholar 8 : Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev2009; 2. CD001423. Google Scholar 9 : Effect of Serenoa repens, lycopene and selenium, on proinflammatory phenotype activation: an “in vitro” and “in vivo” comparison study. Urology2011; 77: 248.e9. Google Scholar 10 : Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter-controlled study. Urol Int2010; 84: 400. Google Scholar 11 : Activity of Serenoa repens, lycopene and selenium on prostatic disease: evidences and hypotheses. Arch Ital Urol Androl2008; 80: 65. Google Scholar 12 : Growth inhibitory efficacy of lycopene and β-carotene against androgen-independent prostate tumor cells xenografted in nude mice. Mol Nutr Food Res2011; 55: 606. Google Scholar 13 : Lycopene induces cell growth inhibition by altering mevalonate pathway and Ras signaling in cancer cell lines. Carcinogenesis2010; 31: 1813. Google Scholar 14 : Antimutagenic effects of lycopene and tomato purée. J Med Food2010; 13: 1443. Google Scholar 15 : Investigation of the selenium metabolism in cancer cell lines. Metallomics2011; 3: 162. Google Scholar 16 : Selenium, but not lycopene or vitamin E, decreases growth of transplantable dunning R3327-H rat prostate tumors. PLoS One2010; 5: e10423. Google Scholar 17 : Survivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition. BMC Cancer2010; 10: 418. Google Scholar 18 : Efficacy of antioxidant vitamins and selenium supplement in prostate cancer prevention: a meta-analysis of randomized controlled trials. Nutr Cancer2010; 62: 719. Google Scholar 19 : Preventive effects of D-004, a lipid extract from Cuban royal palm (Roystonea regia) fruits, on prostate hyperplasia induced with testosterone in intact and castrated rodents. Drugs Exp Clin Res2004; 30: 227. Google Scholar 20 : Dissecting the pathways to death. Leukemia2000; 14: 2035. Google Scholar 21 : Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell1993; 75: 241. Google Scholar 22 : Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol1995; 7: 541. Google Scholar 23 : Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Res2005; 25: 3123. Google Scholar 24 : Mitochondria and apoptosis. Science1998; 281: 1309. Google Scholar 25 : Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation. J Urol2002; 167: 2267. Link, Google Scholar 26 : Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate1998; 37: 77. Google Scholar 27 : The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer2001; 8: 11. Google Scholar 28 : Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res2002; 8: 3438. Google Scholar 29 : Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol1997; 157: 2323. Link, Google Scholar 30 : Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment. Eur J Cancer2010; 46: 3022. Google Scholar © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 186Issue 4October 2011Page: 1524-1529 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.KeywordsSerenoaprostatelycopeneprostatic hyperplasiaseleniumAcknowledgmentsSeR alcoholic extract was provided by Bernett, Milan, Italy.MetricsAuthor Information Domenica Altavilla Section of Pharmacology, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy More articles by this author Alessandra Bitto Section of Pharmacology, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy More articles by this author Francesca Polito Section of Physiology and Human Nutrition, Department of Biochemical, Physiological and Nutritional Sciences, University of Messina, Messina, Italy More articles by this author Natasha Irrera Section of Pharmacology, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy More articles by this author Herbert Marini Section of Physiology and Human Nutrition, Department of Biochemical, Physiological and Nutritional Sciences, University of Messina, Messina, Italy More articles by this author Salvatore Arena Department of Urology, University of Messina, Messina, Italy More articles by this author Vincenzo Favilla Department of Urology, Polyclinic Hospital, University of Catania, Catania, Italy More articles by this author Francesco Squadrito Section of Pharmacology, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy More articles by this author Giuseppe Morgia Department of Urology, Polyclinic Hospital, University of Catania, Catania, Italy More articles by this author Letteria Minutoli Section of Pharmacology, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W1996426161 created "2016-06-24" @default.
• W1996426161 creator A5006216749 @default.
• W1996426161 creator A5010245193 @default.
• W1996426161 creator A5014523351 @default.
• W1996426161 creator A5017321899 @default.
• W1996426161 creator A5026283915 @default.
• W1996426161 creator A5039184636 @default.
• W1996426161 creator A5046567234 @default.
• W1996426161 creator A5046662292 @default.
• W1996426161 creator A5059353158 @default.
• W1996426161 creator A5080680155 @default.
• W1996426161 date "2011-10-01" @default.
• W1996426161 modified "2023-10-01" @default.
• W1996426161 title "The Combination of Serenoa Repens, Selenium and Lycopene is More Effective Than Serenoa Repens Alone to Prevent Hormone Dependent Prostatic Growth" @default.
• W1996426161 cites W1973390591 @default.
• W1996426161 cites W1979313413 @default.
• W1996426161 cites W1980665688 @default.
• W1996426161 cites W1986878226 @default.
• W1996426161 cites W1993684849 @default.
• W1996426161 cites W1997208169 @default.
• W1996426161 cites W2007099638 @default.
• W1996426161 cites W2020359222 @default.
• W1996426161 cites W2026777983 @default.
• W1996426161 cites W2028952750 @default.
• W1996426161 cites W2034555774 @default.
• W1996426161 cites W2056297832 @default.
• W1996426161 cites W2058306191 @default.
• W1996426161 cites W2067598635 @default.
• W1996426161 cites W2080391833 @default.
• W1996426161 cites W2092585267 @default.
• W1996426161 cites W2096391329 @default.
• W1996426161 cites W2113999599 @default.
• W1996426161 cites W2134850272 @default.
• W1996426161 cites W2143556151 @default.
• W1996426161 cites W2150512789 @default.
• W1996426161 cites W2157715384 @default.
• W1996426161 cites W2161185604 @default.
• W1996426161 cites W2167968554 @default.
• W1996426161 cites W2333079922 @default.
• W1996426161 doi "https://doi.org/10.1016/j.juro.2011.05.049" @default.
• W1996426161 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21855911" @default.
• W1996426161 hasPublicationYear "2011" @default.
• W1996426161 type Work @default.
• W1996426161 sameAs 1996426161 @default.
• W1996426161 citedByCount "28" @default.
• W1996426161 countsByYear W19964261612012 @default.
• W1996426161 countsByYear W19964261612013 @default.
• W1996426161 countsByYear W19964261612014 @default.
• W1996426161 countsByYear W19964261612015 @default.
• W1996426161 countsByYear W19964261612016 @default.
• W1996426161 countsByYear W19964261612017 @default.
• W1996426161 countsByYear W19964261612018 @default.
• W1996426161 countsByYear W19964261612019 @default.
• W1996426161 countsByYear W19964261612021 @default.
• W1996426161 countsByYear W19964261612022 @default.
• W1996426161 countsByYear W19964261612023 @default.
• W1996426161 crossrefType "journal-article" @default.
• W1996426161 hasAuthorship W1996426161A5006216749 @default.
• W1996426161 hasAuthorship W1996426161A5010245193 @default.
• W1996426161 hasAuthorship W1996426161A5014523351 @default.
• W1996426161 hasAuthorship W1996426161A5017321899 @default.
• W1996426161 hasAuthorship W1996426161A5026283915 @default.
• W1996426161 hasAuthorship W1996426161A5039184636 @default.
• W1996426161 hasAuthorship W1996426161A5046567234 @default.
• W1996426161 hasAuthorship W1996426161A5046662292 @default.
• W1996426161 hasAuthorship W1996426161A5059353158 @default.
• W1996426161 hasAuthorship W1996426161A5080680155 @default.
• W1996426161 hasConcept C191897082 @default.
• W1996426161 hasConcept C192562407 @default.
• W1996426161 hasConcept C2777535023 @default.
• W1996426161 hasConcept C2780022147 @default.
• W1996426161 hasConcept C28781525 @default.
• W1996426161 hasConcept C553756173 @default.
• W1996426161 hasConcept C59822182 @default.
• W1996426161 hasConcept C71924100 @default.
• W1996426161 hasConcept C86803240 @default.
• W1996426161 hasConcept C98274493 @default.
• W1996426161 hasConceptScore W1996426161C191897082 @default.
• W1996426161 hasConceptScore W1996426161C192562407 @default.
• W1996426161 hasConceptScore W1996426161C2777535023 @default.
• W1996426161 hasConceptScore W1996426161C2780022147 @default.
• W1996426161 hasConceptScore W1996426161C28781525 @default.
• W1996426161 hasConceptScore W1996426161C553756173 @default.
• W1996426161 hasConceptScore W1996426161C59822182 @default.
• W1996426161 hasConceptScore W1996426161C71924100 @default.
• W1996426161 hasConceptScore W1996426161C86803240 @default.
• W1996426161 hasConceptScore W1996426161C98274493 @default.
• W1996426161 hasIssue "4" @default.
• W1996426161 hasLocation W19964261611 @default.
• W1996426161 hasLocation W19964261612 @default.
• W1996426161 hasOpenAccess W1996426161 @default.
• W1996426161 hasPrimaryLocation W19964261611 @default.
• W1996426161 hasRelatedWork W1995515455 @default.
• W1996426161 hasRelatedWork W2159373348 @default.
• W1996426161 hasRelatedWork W2325248882 @default.
• W1996426161 hasRelatedWork W2336380136 @default.
• W1996426161 hasRelatedWork W2724223663 @default.

• next